ClinicalTrials.gg
Enrolling by invitationNCT07109609TMTSUpdated Sep 16, 2025

Topical Menthol For Tear Secretion

A Phase 2 interventional study of Topical application of 20% menthol solution in MCT oil. and Topical Placebo Oil rolled onto the cheek. in Healthy and Dry Eyes, sponsored by Reinhold Vieth. Enrolling by invitation at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Reinhold Vieth · Phase 2, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Dry Eye Syndromes with a site in Canada — 5 open to participants now, 5 under way, 1 of them phase 3. Dry Eye Syndromes · Canada.

Planned enrollment
28th of 37
30 · median 48
Started
2025
the only one that year
Phase 2
4 of 45
1 open now
Registered
43rd of 45
by date

Among the 45 studies in Dry Eye Syndromes with a site in Canada, this one is the 28th largest by planned enrollment of the 37 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 2, and was the 43rd registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 45 studies in Dry Eye Syndromes with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Dry Eye Syndromes with a site in Canada, or all of them as a file.
02

Study summary

Tears are the natural way to keep eyes moist, and tears are important for good vision and healthy eyes. Eyes without enought tears get dry and sore.

The natural and normal way to stimulate secretion of tears is by turning on cold sensors that are located on the cornea of the eye. Tear are normally released across the eyeball in a finely balanced system that balances out that natural evaporation. But sometimes there is not enough tear secretion to balance out the evaporation of tears and eyes can get sore.

The aim here is to test whether menthol in its vapor form may possibly turn on those cold sensors and thus cause secretion of tears. Use of menthol vapors may be like having a switch to release more tears.

The aim of this clinical trial is to test the hypothesis that a menthol solution applied onto a cheek will release enough menthol vapor into the air flowing up over the eye's cornea to stimulate cold sensors enough to make a tear flow from the eye.

If the hypothesis that menthol safely stimulates tear secretion in healthy people proves to be correct, then this clinical trial may inspire more new research into the use of menthol as an alternative to the use of eye drops for some people.

Read the detailed description

This is a proof-of-principle clinical trial. It is a double-blind, placebo-controlled, randomized clinical trial. Participants are not being seen by a physician for eye disease, and there is a 50% probability that a participant will receive active treatment, or 50% probability that they will just receive the carrier oil with nothing in it (placebo).

03

Conditions studied

  • Healthy
  • Dry Eyes

Keywords

  • tear secretion
  • dry eyes
  • eye drops
  • menthol
  • vapor
  • cornea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Not under care of an opthalmologist for treatment of dry-eyes

Exclusion criteria

Exclusion Criteria:

    • Excluded if "Yes" to any of the questions below.

      • Are you allergic to menthol or to menthol-containing products like tooth paste or certain cold remedies?
      • Are you wearing contact lenses during the time of testing? ________
      • Are there tears present prior to applying the menthol? ________
      • Did you use of eye drops during the hour before participation? ________
      • Do you have broken, irritated, sensitive skin and/or acne at or around application site? ________
      • Do you have a history of atopy, allergic diseases at the skin of your cheeks?
      • Do you have Stevens-Johnson syndrome, which is any known skin response to chemical, thermal, or radiation injury to the application area? ____
05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Topical Menthol in Oil

    Menthol solution rolled onto the cheek below rim of a pair of glasses

    Drug: Topical application of 20% menthol solution in MCT oil.

  • Placebo comparator
    Topical Placebo Oil only

    Oil vehicle only rolled onto the cheek below rim of a pair of glasses

    Drug: Topical Placebo Oil rolled onto the cheek.

Interventions

  • DrugTopical application of 20% menthol solution in MCT oil.

    To facilitate reproducible and correct application of the solution, the subject wears glasses while the product is applied. The solution is rolled onto one cheek by rolling it to an area of about 2cm X 2cm at the cheekbone, underneath the bottom rim of the glasses worn. This method delivers about 12 mg solution, i.e. 2.4 mg menthol to one cheek. Or this method delviers 12 mg of placebo oil. The subject then sits in still air for 5 minutes, at which point tissue is wiped across the skin below the bottom eyelashes to permit the weighing of secreted tear.

  • DrugTopical Placebo Oil rolled onto the cheek.

    To facilitate reproducible and correct application of the Placebo oil, the subject wears glasses while the product is applied. The Placebo oil is rolled onto one cheek by rolling it to an area of about 2cm X 2cm at the cheekbone, underneath the bottom rim of the glasses worn. This method delivers zero active agent. The subject then sits in still air for 5 minutes, at which point tissue is wiped across the skin below the bottom eyelashes to permit the weighing of secreted tear.

06

What researchers measure

Primary outcomes

  1. Objective measure of tear stimulation Yes or No

    The outcome is the binary yes/no observation of active tear secretion that overflows to the skin below the bottom eyelashes. Subject sits in still air while wearing glasses to ensure correct positioning of the topical application. The solution of menthol or placebo is dispensed from a roller-ball bottle to the right eye only, onto an area about 2cm x 2 cm just below the bottom rim of the glasses; that is, inferior to the pupil, and in line with the bottom of the nose. Within 5 minutes of sitting in still air, If moisture is evident below the bottom eyelashes, glasses are removed and tissue is dabbed, or wiped under bottom eyelash to take up the tear. If that wipe increases the weight of the tissue by at least 6 milligrams, then a "Yes" response is recorded. If after 5 minutes a wipe of tissue across the bottom eyelashes of the right eye does not increase the weight of tissue by at least 6 milligrams, a "No" is recorded to indicate that there was no increase in tear secretion.

    Time frame: Participant is observed for 5 minutes after application, to record tear-weight data, and the related questions that are asked are completed within 10 minutes after applicaiton.

  2. Weight of tear

    The actual measured weight of the tear(s) collected onto the tissue, from below the right eye.

    Time frame: Measured at 5 minutes after dose application.

  3. Was there a subjective difference between left and right eyes in terms of sense if moisture

    Response to the question: " Which eye feels more moist? Left eye more moist or No difference (both same) or ….Right eye more moist"

    Time frame: 5 to 10 minutes after application

  4. Weight of nasal secretion blown into tissue.

    The purpose is to test whether there is evidence of shared innervation of TRPM8 receptors (the menthol-responsive sensors for cold) in cornea and nasal subepithelium. The particpant holds closed the left nostril, while blowing into a tissue from the right nostril. The increase in weight of tissue is measured.

    Time frame: Within 10 minutes of applying the dose.

Secondary outcomes

  1. Weight of nasal secretion

    Subject blows their nose into a tissue, and the increase in tissue weight is recorded.

    Time frame: 5 to 10 minutes after application

  2. Discomfortable feeling at the treated eye.

    At your right eye, was there anything uncomfortable feeling? Nothing mild moderate severe (choose one)

    Time frame: 10 minutes

  3. Degree of cooling or pain at the skin where the dose was applied.

    At the skin of the cheek, where it was rolled on, did you feel (choose one) COOLING OR NOTHING OR PAIN If cooling or pain, how strong was the feeling? (choose one) Nothing mild moderate severe

    Time frame: 10 minutes

  4. Did the procedure increase sense of runny nose?

    Did you feel a runny nose, or nasal secretion during the 5 minutes of waiting? No or Yes And if Yes, at which nostril? Left or Right or Both nostrils

    Time frame: 10 minutes

07

Study locations

1 site
  • Stearacl Incorporated.
    Toronto, Ontario M4K1X4, Canada
08

References and documents

Individual participant data

Plan to share: Yes — A spreadsheet of anonymized IPD collected throughout the trial may be made upon inquiry with the corresponding author of any peer-reviewed publication ensuing from this work.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 1 month after final publication

Access criteria: The senior author of any ensuing publication will correspond with suitably qualified investigators, to discuss the type and form of data made available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Nov 2025, 2 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's planned 2 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 7, 2025
StartActual
Aug 17, 2025
Primary completionEst.
Nov 7, 2025
CompletionEst.
Dec 1, 2025
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07109609
Lead sponsor
Reinhold Vieth
Collaborators
Stearacl Inc
Responsible party
Reinhold Vieth (CEO Stearacl Inc, Canada, Stearacl Inc) — Sponsor-investigator
First posted
Aug 7, 2025
Start date
Aug 17, 2025
Primary completion
Nov 7, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Sep 16, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion